Evidence map›Paper›PMID 34950214›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2021

The Diagnostic Value of Serum Ang, VEGF, and CRP Combined with the Chinese Medicine Antitumor Formula in the Treatment of Advanced Renal Carcinoma.

Nana Dong, Shengmin Zhang, Shuangjun Zhang, Qiongqiong Zhao, Donghua Zhang, Feng Chen

Abstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nana DongDepartment of Oncology (I), Yantaishan Hospital, Yantai 264000, China.ORCID https://orcid.org/0000-0002-8549-0998
Shengmin ZhangPIVAS, Qingdao Central Hospital, Qingdao University, Qingdao 266000, China.ORCID https://orcid.org/0000-0001-7219-1000
Shuangjun ZhangDepartment of Imaging, Zhangqiu District People's Hospital, Jinan 250200, China.ORCID https://orcid.org/0000-0002-5215-586X
Qiongqiong ZhaoDepartment of Paediatrics (II), Zhangqiu District People's Hospital, Jinan 250200, China.ORCID https://orcid.org/0000-0001-7240-8628
Donghua ZhangTumor-Chemotherapy Department, Zhangqiu District People's Hospital, Jinan 250200, China.ORCID https://orcid.org/0000-0002-4656-7577
Feng ChenInternal Medicine Department, Weifang Municipal Government Hospital, Jinan 250200, China.ORCID https://orcid.org/0000-0001-5001-7693

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore the diagnostic value of serum angiopoietin (Ang), vascular endothelial growth factor (VEGF), and C-reactive protein (CRP) combined with the Chinese medicine antitumor formula in the treatment of advanced renal carcinoma.

methodsRetrospective analysis was performed for the data of 60 patients with advanced renal cancer admitted at Yantaishan Hospital from February 2019 to February 2020. All patients were treated with Chinese medicine antitumor formula. The serum Ang, VEGF, and CRP levels in venous blood samples were detected before and after treatment. Sensitivity, specificity, and AUC of combined serum Ang, VEGF, and CRP were analyzed utilizing the receiver operating characteristic curve (ROC) (95% CI).

resultsThere were 52 cases of clear-cell carcinoma (86.7%), 7 cases of papillary carcinoma (11.7%), and 1 case of chromophobe renal cell carcinoma (1.7%). The average tumor diameter was (9.67 ± 0.65) cm, and the KPS score was (74.68 ± 1.52). About 75% of the patients had metastasis. After treatment, the level of serum Ang, VEGF, and CRP was immensely lower compared to that before treatment (

conclusionThe combined detection of serum Ang, VEGF, and CRP has high diagnostic value for patients with advanced renal cancer treated with Chinese medicine antitumor formula.

Identifiers

PMID34950214
PMCPMC8692006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.